Caliper Life Sciences, Inc. (NASDAQ: CALP), today reported its financial results for the first quarter of 2011. First quarter revenue increased to $35.8 million, or 25%, from $28.7 million in the same period of 2010. This increase was principally driven by year-over-year 26% organic growth of comparable product, service and license revenues. Cambridge Research & Instrumentation, Inc. ("CRi"), which Caliper acquired in December 2010, contributed $2.6 million to first quarter 2011 revenues. This contribution was offset by a similar amount of revenue in the first quarter of 2010 from product lines that Caliper divested in May 2010.
Caliper reported a 2011 first quarter GAAP net loss of $2.6 million, or $0.05 per basic and diluted share, compared to a net loss of $2.2 million, or $0.04 per basic and diluted share, in the same period of 2010. Non-GAAP net income, which is adjusted for intangibles amortization, acquisition-related costs and restructuring charges, was $0.3 million in the first quarter of 2011, or $0.01 per diluted share, compared to a non-GAAP net loss of $0.9 million, or $0.02 per diluted share, in the same period of 2010.
Caliper reported cash flows from operations of $0.1 million during the first quarter of 2011 compared to $(0.8) million during the same period of 2010, and also reported cash and marketable securities of approximately $35.2 million and no outstanding short-term borrowings under its credit facility as of March 31, 2011.
Caliper also stated that it increased its full year 2011 revenue estimates.
Please refer to the tables included under "Reconciliation of GAAP to Non-GAAP Financial Measures" for itemized reconciliations between GAAP and non-GAAP financial measures appearing in this release.
"We are pleased with our first quarter results, progress with the integration of CRi, and overall positive momentum going into the second quarter. We had strong revenue growth in each of our strategic business units as we continue to transform Caliper into a premier provider of tools, technologies and services enabling personalized medicine. In addition, we were pleased to deliver higher gross margins and positive operating cash flow for our third consecutive quarter," commented Kevin Hrusovsky, President and CEO of Caliper Life Sciences. "We remain encouraged regarding the strength of our end markets, namely next generation sequencing, molecular diagnostics, biologics, tissue analysis and imaging, and the momentum of our new products and services associated with personalizing medicine / healthcare," added Hrusovsky.
Analysis of First Quarter 2011 Results
- Caliper's revenues increased 25% in the first quarter of 2011 compared to the same period of 2010. Non-GAAP revenues grew 37% in the first quarter of 2011 compared to the same period of 2010, comprised of 26% organic growth, 10% acquisition-driven growth and 1% favorable currency benefit.
- Revenues from Caliper's Imaging business unit grew 44%, comprised of 25% growth from existing pre-clinical in vivo molecular imaging product lines due to continuing strong market demand and 19% acquisition-driven growth added by CRi's tissue analysis products.
- Revenues from Caliper's Research business unit grew 22% on a non-GAAP basis excluding the impact from certain Automation product lines divested in May 2010. Revenue related to Caliper's LabChip products grew 30% driven by strong demand for research applications, next-generation sequencing and adoption for molecular diagnostic applications. Revenue related to Caliper's ongoing Automation products grew 11% on a non-GAAP basis, driven by growing application needs for genomic sample preparation and next-generation sequencing.
- Revenues from Caliper's CDAS business unit grew 93% primarily attributable to revenues from CDAS' contract with the Environmental Protection Agency under its ToxCast™ screening program.
- First quarter 2011 total gross margin was approximately 52%, consistent with the same period in 2010. Combined product and service gross margin increased by 143 basis points to approximately 48% from 47% in the same period in 2010. Purchase accounting adjustments to value acquired CRi inventory at fair value negatively impacted combined product and service gross margin by 145 basis points. Net of purchase accounting effects, the improvement in product and service gross margin resulted from higher CDAS revenue, favorable changes in product mix and lower raw material product costs.
- First quarter operating expenses (research and development, and selling, general and administrative costs) increased 26% to $19.1 million, from $15.2 million in the same period in 2010. Approximately one-half of the increase was attributable to incremental operating expenses incurred as a result of CRi's operations and the remainder of expense increase resulted primarily from increased investment in sales and marketing efforts and increased legal expenses due to ongoing litigation.
- In the first quarter, Caliper recorded a restructuring charge of approximately $0.9 million which was primarily comprised of a $0.5 million charge for additional severance costs in connection with the acquisition of CRi. Caliper also recorded $0.4 million in idle facility charges in connection with updating sublease assumptions. Caliper is also anticipating a further facility restructuring charge of approximately $1.0 million in the third quarter of 2011 upon the full closure of CRi's manufacturing facility in Woburn, Mass.
Recent Business Highlights
- Caliper sponsored a symposium on personalized medicine at the American Association for Cancer Research (AACR). At this session, presenters from Novartis and Stanford described the impact of Caliper's tissue and in vivo molecular imaging systems on translational medicine and personalized cancer treatment, and presenters from Caliper described how Caliper's disruptive technologies enable personalized medicine and oncology research. Approximately 250 oncology researchers attended this well-received session.
- Caliper completed Phase IIb primary screening under CDAS' EPA ToxCast contract and was awarded $3.1 million of new EPA task orders to fund the next stages of ToxCast work. The Phase I ToxCast results and initial conclusions regarding toxicology correlations were published in the scientific journal Toxicology in March 2011. ToxCast data and resulting predictive models are being used by Caliper to identify possible safety liabilities of environmental chemicals, cosmetic ingredients, and/or pharmaceuticals, and to identify biomarkers for potential rescue of drug candidates through personalized medicine approaches.
- Caliper formed a research collaboration with Denver-based Catholic Health Initiatives to provide Caliper with access to human tumor samples to develop improved methods for evaluating and predicting the efficacy of new cancer drugs and for providing enhanced solutions for personalized medicine and patient stratification in oncology.
- Kevin Hrusovsky, Caliper President and CEO, was an invited speaker and panel participant at the Massachusetts Biotechnology Council's annual conference on the topic of "Translational Medicine – Genomics, Clinical Implementation, Pharmaco-Kinetics, and Prospective Healthcare" on March 21st. His talk highlighted the role of technology companies working with research hospitals, pharma and academia in being able to accelerate personalized medicine. The panel included thought leaders from Pfizer, Mass General Hospital, The Spinal Muscular Atrophy Foundation and Constellation Pharmaceutics and was attended by over 200 scientists and healthcare professionals.
Caliper Life Sciences, Inc.